NASDAQ · RLMD
Relmada Therapeutics, Inc.
$3.44+$0.09 (+2.69%)
Relmada Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.0% below the high.
Loading market information…
NASDAQ · CBUS · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Cibus, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.79% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Cibus, Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.20. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Cibus, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 8, 2025 |
| -$1.34-91.43% vs estimate |
| $1.03M-9.3% vs estimate |
| Q4 2024 | Mar 20, 2025 | -$0.87-27.94% vs estimate | $1.21M+5.39% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | $0.06+106.74% vs estimate | $1.67M+156.46% vs estimate |
|---|
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.44+$0.09 (+2.69%)
Relmada Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.0% below the high.
$3.90+$0.25 (+6.85%)
CAMP4 Therapeutics Corporation’s quoted price sits in the lower half of its reported 52-week range, 49.68% below the high.
$2.65$0.00 (0.0%)
Repare Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.38% below the high.
$7.80-$0.19 (-2.32%)
Immunic, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.28% below the high.
$3.81+$0.05 (+1.33%)
Unicycive Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.41% below the high.
$0.43+$0.02 (+4.66%)
Vaxart, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.17% below the high.
$1.76-$0.03 (-1.68%)
Acrivon Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 50.56% below the high.
$1.35-$0.03 (-2.17%)
PMV Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.32% below the high.
